Lantheus Alpha Therapy, LLC filed a Form 4 with the SEC on September 4, 2026, disclosing the sale of common stock in Perspective Therapeutics, Inc. (NASDAQ:CATX) on September 2, 2026.

Key Highlights

  • Shares sold: Lantheus Alpha Therapy, LLC disposed of 42,129 shares of Perspective Therapeutics common stock on September 2, 2026.
  • Weighted average price: The reported sale price was $3.1147 per share, a weighted average across multiple transactions.
  • Price range: Individual transactions occurred at prices ranging from $3.025 to $3.235, inclusive.
  • Remaining ownership: Following the sale, Lantheus Alpha Therapy, LLC directly held 11,521,296 shares of common stock.
  • Reporting persons: Both Lantheus Alpha Therapy, LLC and its parent, Lantheus Holdings, Inc., are identified as reporting persons, each checked as a 10% owner.

Lantheus Alpha Therapy Reduces Stake in Perspective Therapeutics

According to the filing, Lantheus Alpha Therapy, LLC, a wholly owned indirect subsidiary of Lantheus Holdings, Inc., sold 42,129 shares of Perspective Therapeutics, Inc. common stock on September 2, 2026, under transaction code "S." The shares were disposed of at a weighted average price of $3.1147, with individual sales executed at prices ranging from $3.025 to $3.235, inclusive. The filing notes that full information on the number of shares sold at each separate price is available upon request to Perspective Therapeutics, any security holder, or SEC staff.

After the reported transaction, Lantheus Alpha Therapy, LLC directly held 11,521,296 shares of Perspective Therapeutics common stock, according to the filing. The filing explains that Lantheus Holdings, Inc. "may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership," consistent with SEC rules and regulations. Lantheus Holdings, Inc. is listed as a co-reporting person and is also identified as a 10% owner of Perspective Therapeutics.

The Form 4 was signed by Eric M. Green, Assistant Corporate Secretary, on behalf of both Lantheus Holdings, Inc. and Lantheus Alpha Therapy, LLC, and was filed on September 4, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing reported the sale of 42,129 shares of Perspective Therapeutics, Inc. (NASDAQ:CATX) common stock by Lantheus Alpha Therapy, LLC on September 2, 2026, at a weighted average price of $3.1147, leaving a remaining direct holding of 11,521,296 shares.